Effects of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide Source: Annual Congress 2009 - New bronchodilators Year: 2009
Effect of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006
Roflumilast and its active metabolite roflumilast N-oxide do not interact with R- and S-warfarin Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003
Effects of steady-state female hormones on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500µg roflumilast in the morning versus evening Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Pharmacokinetic characteristics of roflumilast and its active metabolite roflumilast-N-oxide are not affected by food intake Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006
Equivalent pharmacokinetics of the active metabolite of ciclesonide when using the ciclesonide-MDI with and without a spacer Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Pharmacokinetics of roflumilast and its active metabolite roflumilast-N-oxide in middle aged and young subjects Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor Source: International Congress 2017 – Asthma management Year: 2017
Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001
Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500μg to 1000μg are dose-linear in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
Pharmacodynamics of moxifloxacin and four macrolides in the absence or presence of macrophages Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Comedication with ciprofloxacin does not change pharmacokinetics of mycophenolic acid after lung transplantation Source: Eur Respir J 2002; 20: Suppl. 38, 349s Year: 2002
No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001